Nob Hill Therapeutics, Inc.
Albuquerque, NM
- UEI
- EL4UKHCBUCM3
- CAGE
- 7RJH9
- Primary NAICS
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 5901 Indian School Rd NE #209, Albuquerque, NM 87110, USA
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Parion Sciences, Inc. | Durham, NC | 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) |
| Quench Medical Inc. | Saint Paul, MN | — |
| Nupeak Therapeutics Inc. | Clayton, MO | — |
| Kevirx Inc. | Charlottesville, VA | — |
| Quercus Molecular Design, LLC | Avon, CT | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
About the company
Nob Hill Therapeutics, Inc., doing business as Nob Hill Therapeutics Inc., is a for-profit corporate entity registered in SAM.gov to receive federal government awards. It specializes in the development of dry powder formulations and delivery devices for respiratory therapeutics.
Nob Hill Therapeutics, Inc. has received several federal grant awards from agencies like the National Institutes of Health (NIH) and the National Heart, Lung, and Blood Institute (NHLBI). These awards aim to advance the development of innovative therapies for conditions like metastatic lung cancer and fungal infections. One notable project involves an aerosolized epigenetic therapy (5AZA-DP) delivered via Nob Hill's DryNeb dry powder nebulizer device for treating metastatic lung cancer. This $861,087 grant from the NIH National Cancer Institute supports formulation scale-up, aerosol performance evaluation, and GLP toxicology studies to enable filing an Investigational New Drug (IND) application with the FDA for clinical trials. Another significant project is the development of NH101, a dry powder amphotericin B formulation combined with the DryNeb device for treating susceptible and multidrug-resistant aspergillus/fungal infections, particularly in cystic fibrosis and asthma-associated allergic bronchopulmonary aspergillosis. This project, funded by NHLBI grants totaling over $3 million, aims to refine the DryNeb for clinical use, scale up the amphotericin B formulation, and conduct a first-in-human enabling repeat dose GLP toxicology study.
Quick answers
Is Nob Hill Therapeutics, Inc. registered in SAM.gov?
Yes. Nob Hill Therapeutics, Inc.'s SAM.gov registration is active through June 12, 2027.
What is Nob Hill Therapeutics, Inc.'s most recent federal award?
Nob Hill Therapeutics, Inc.'s most recent federal grant award is Aerosolized epigenetic therapy for metastatic lung cancer (R44CA281538), from National Cancer Institute (NIH), on September 19, 2023.
On GovTribe
See Nob Hill Therapeutics, Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors